That in turn will affect the ability and willingness of Indian pharma companies to invest in capacity expansion and research spending which at present is in the range of 8-10% of their sales revenue compared to 20% for multinationals. Obviously, if indigenous pharma companies aren't able to fund the ...
Read more: Beware price controls on medicines: It will deter pharma industry and choke the supply of quality ...